Jeanette Jakobsson

Banner image with text: 'Stay informed with the latest IP news' and the following words listed: Insights, Interviews, Webinars.

India’s Supreme Court rejects patent plea by Novartis for the cancer drug Glivec

By Jeanette Jakobsson | Posted on April 18, 2013

For years, India did not offer any patent protection for chemical compounds, but was obliged to do this after joining the World Trade Organization. In 2005, the patent protection act therefore was amended to also include such compounds, but only if they proved significant clinical efficacy enhancements over already patented compounds, Section 3(d) of the Indian...

Tags: Bayer, Glivec, Novartis, Roche

Poverty versus patenting in India – round two

By Jeanette Jakobsson | Posted on November 22, 2012

Earlier this year the first compulsory license, regarding the anti-cancer drug Sorafenib, was granted in India. (See previous blog post.) The compulsory license was granted inter alia on the ground that the patented invention was not available to the public at a reasonable affordable price. The battle towards affordable medicaments in India continues. In a...

Tags: compulsory license, drug patents, India, Pharmaceuticals

India Grants the First Compulsory License

By Jeanette Jakobsson | Posted on March 30, 2012

The Compulsory License Application No. 1 of 2011, the first of its kind in the history of the Indian Patents Act 1970, concerns the anti-cancer drug Sorafenib, where the patentee is Bayer Corporation and the applicant for a compulsory license is Natco Pharma Limited. The anti-cancer drug Sorafenib, sold under the brand name NEXAVAR, is...

Tags: compulsory license, drug patents, India

Recent contributors

Laura Stravinskaite

Laura Stravinskaite

Senior Associate, Attorney at Law

Ai-Leen Lim

Ai-Leen Lim

Partner, Attorney at Law, Group Vice President

Ashley Zhao

Ashley Zhao

Partner, Attorney at Law, Business Area Manager

Troels Peter Rørdam

Troels Peter Rørdam

Senior Counsel, European Patent Attorney

Mikkel Roed Trier

Mikkel Roed Trier

Partner, European Patent Attorney, UPC Representative, Business Area Manager